Acquisition Announced
Ipsen acquisition of Memo Therapeutics
€200m consideration
Announced 7 Jul 2026
Advisers
Memo Therapeutics
Target
- Financial adviser
- Legal adviser
Ipsen
Acquirer
Not disclosed
- Target
- Memo Therapeutics
- Acquirer
- Ipsen
- Target based in
- Switzerland
- Buyer based in
- France
- Sector
- Biotech
Similar deals
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Relativity Acquisition Corp. and Instinct Bio Technical Company merger Feb 2025 · US$225m · Biotech
- Eli Lilly acquisition of Engage Bio May 2026 · US$202m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Bayer acquisition of Perfuse Therapeutics May 2026 · US$300m · Biotech
Sources
- 2026 Centerview Partners: Centerview as exclusive financial advisor to Memo Therepeutics on their sale to Ipsen centerviewpartners.com
- 7 Jul 2026 Goodwin Guides Memo Therapeutics AG on Acquisition by Ipsen for Over €700 Million goodwinlaw.com

